Immunoassay Market worth $49.6 billion by 2027
According to the research report published by MarketsandMarkets™ INC "Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecasts to 2027", is projected to reach USD 49.6 billion by 2027 from USD 40.2 billion in 2022, at a CAGR of 4.3% during the forecast period. The immunoassay market is driven by increasing incidence of chronic and infectious diseases, increasing adoption of immunoassay-based POC testing and rapid testing, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.

Download PDF Brochure

Browse
• 361 Market data Tables
• 53 Figures
• 427 Pages and in-depth TOC on "Immunoassay Market - Global Forecast to 2027"

Some of the prominent key players are:
Abbott Laboratories (US),
F. Hoffmann-La Roche (Switzerland),
Siemens Healthineers (Germany) and many more......
Opportunities: Advancements in systems and technologies

Key players and researchers have several advanced, reliable, and economic immunoassay platforms for disease diagnostics. Automated systems offer flexibility in scale-up, massive sampling volume, faster processing, vast storage, and high efficacy required for COVID-19 diagnosis and management. Recent developments in this market include:
In September 2021, Thermo Fisher Scientific, Inc. (US) launched its fully automated analyzers, Thermo Scientific Gallery Enzyme Master and Thermo Scientific Gallery Plus Enzyme Master, which are specifically designed for enzyme assay applications.
In May 2021, Beckman Coulter (US) launched its fully automated and qualitative COVID-19 immunoassay, Access SARS-CoV-2 IgG (1st IS). The immunoassay is a fully quantitative lab-based Immunoglobulin G (IgG) serology test intended to measure the number of antibodies against the virus that causes COVID-19.
In February 2021, F. Hoffmann-La Roche (Switzerland) launched the SARS-CoV-2 Rapid Antigen Test Nasal with patient self-collection.
Top Segments
The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the high consumption and repeat purchases of reagents & kits and the increasing number of immunoassay tests performed across the globe.
The immunoassay market is segmented into ELISA, rapid tests, ELISpot, western blotting, radioimmunoassays, and other technologies. Rapid tests are used to screen donated blood for HIV, HCV, HBV, and HCG antibodies. Rapid tests are effective as an aid in POC diagnosis, especially in emergency and primary care settings.
Based on specimens, the immunoassay market is segmented into blood, saliva, urine, and other specimens. In 2021, blood specimens accounted for the largest share of the immunoassay market.
The global immunoassay market is segmented into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, and other applications. Infectious diseases segment to register the highest growth rate among applications during the forecast period.
The hospitals & clinics segment accounted for the largest share of the immunoassay market, by end user.
Request Sample Pages

North America is the largest regional market for immunoassay market

The global immunoassay market has been segmented into five major regions—North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America. In 2021, North America dominated the global immunoassay market in 2021. The large share of the North American market is primarily driven by the rising prevalence of chronic diseases, increasing geriatric population, and the presence of leading national clinical laboratories, and the easy accessibility of technologically advanced instruments.

Download The PDF Brochure of Trending Related Industry Reports
Point of Care Diagnostics Market
Immunofluorescence Assay Market
Newborn Screening Market
Lateral Flow Assays Market
In Vitro Diagnostics Market
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.